ICER will assess the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The report is expected to focus on four therapies for the prevention of hereditary angioedema attacks: lanadelumab (Shire), which is currently under review by the FDA with an approval decision expected in August of 2018, and three C1 esterase inhibitors (Haegarda®, CSL Behring; Cinryze®, Shire; and Ruconest®, Pharming*). This list is tentative and subject to change.
*Ruconest (Pharming) was removed from the ICER review in September 2018 because the treatment is no longer under consideration for FDA approval for long-term prophylaxis.
For questions or additional information, please contact email@example.com
California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612
CTAF will convene to review ICER's assessment of therapies for hereditary angioedema.
Open to public comment until May 2, 2018. For more information about submitting a public comment, including formatting specifications, please see our engagement page.